Online inquiry

IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3257MR)

This product GTTS-WQ3257MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Lombar radicular pain research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3257MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7491MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ11312MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ5539MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ11620MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ3561MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ9877MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ15854MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ9076MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW